DIVA Laboratories Ltd Cash Flow-to-Debt Ratio
DIVA Laboratories Ltd cash flow-to-debt ratio. DIVA Laboratories Ltd (4153) has a Cash Flow-to-Debt Ratio of -0.04x as of March 2026, meaning its operating cash flow of NT$-16.94 Million could theoretically repay 0% of its total liabilities (NT$447.40 Million) in one year. Check 4153 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of DIVA Laboratories Ltd (2017–2025)
Cash flow-to-debt ratio of DIVA Laboratories Ltd from 2017 to 2025. Historical debt coverage capacity for DIVA Laboratories Ltd across 9 annual periods. Check 4153 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
DIVA Laboratories Ltd Cash Flow-to-Debt Ratio by Year (2017–2025)
DIVA Laboratories Ltd cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for DIVA Laboratories Ltd. For the full cash flow conversion analysis, see 4153 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | NT$20.77 Million | NT$324.52 Million | ▼ -87.0% |
| 2024 | 0.49x | NT$123.14 Million | NT$249.94 Million | ▼ -58.9% |
| 2023 | 1.20x | NT$252.91 Million | NT$210.93 Million | ▲ +286.0% |
| 2022 | 0.31x | NT$73.19 Million | NT$235.62 Million | ▲ +632.5% |
| 2021 | -0.06x | NT$-11.39 Million | NT$195.27 Million | ▲ +56.4% |
| 2020 | -0.13x | NT$-16.64 Million | NT$124.34 Million | ▼ -142.7% |
| 2019 | 0.31x | NT$52.66 Million | NT$168.09 Million | ▼ -49.4% |
| 2018 | 0.62x | NT$86.02 Million | NT$138.87 Million | ▲ +280.8% |
| 2017 | 0.16x | NT$41.45 Million | NT$254.84 Million | — |